Thymosin beta-4 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
== External links == Calvete JJ (1995). "On the structure and function of platelet integrin alpha IIb beta 3, the fibrinogen receptor". Proc. Soc. Exp. Biol. Med. 208 (4): 346–60. doi:10.3181/00379727-208-43863a. PMID 7535429. Garner Stephen F., Campbell Kate, Metcalfe Paul, Keidan Jane, Huiskes Elly, Dong Jing-Fei, Lopez Jose A., Ouwehand Willem H. (2002). "Glycoprotein V: the predominant target antigen in gold-induced autoimmune thrombocytopenia" (PDF). Blood. 100 (1): 344–346. doi:10.1182/blood.V100.1.344. PMID 12070047.{{cite journal}}: CS1 maint: multiple names: authors list (link) Dumin J A, Dickeson S K, Stricker T P, Bhattacharyya-Pakrasi M, Roby J D, Santoro S A, Parks W C (2001). "Pro-collagenase-1 (matrix metalloproteinase-1) binds the alpha(2)beta(1) integrin upon release from keratinocytes migrating on type I collagen". J. Biol. Chem. 276 (31): 29368–74. doi:10.1074/jbc.M104179200. PMID 11359786.{{cite journal}}: CS1 maint: multiple names: authors list (link) http://www.reference.md/files/D019/mD019038.html Online Medical Dictionary, Platelet membrane glycoproteins Platelet+membrane+glycoproteins at the U.S. National Library of Medicine Medical Subject Headings (MeSH) http://www.ojrd.com/content/1/1/46/figure/F1?highres=y http://circ.ahajournals.org/content/99/1/e1/F4.large.jpg
Kane, a scientist at Pfizer, suggested using a deep-tank fermentation method for producing large quantities of pharmaceutical-grade penicillin. Large-scale production resulted from the development of a deep-tank fermentation plant by the chemical engineer Margaret Hutchinson Rousseau. As a direct result of the war and the War Production Board, by June 1945 over 646 billion units per year were being produced. G. Raymond Rettew made a significant contribution to the American war effort by his techniques to produce commercial quantities of penicillin, wherein he combined his knowledge of mushroom spawn with the function of the Sharples Cream Separator. By 1943 Rettew's lab was producing most of the world's penicillin. During the Second World War penicillin made a major difference in the number of deaths and amputations caused by infected wounds amongst Allied forces, saving an estimated 12–15% of lives. Availability was severely limited, however, by the difficulty of manufacturing large quantities of penicillin and by the rapid renal clearance of the drug, necessitating frequent dosing. Methods for mass production of penicillin were patented by Andrew Jackson Moyer in 1945. Florey had not patented penicillin, having been advised by Sir Henry Dale that doing so would be unethical. Penicillin is actively excreted, and about 80% of a penicillin dose is cleared from the body within three to four hours of administration.
Pat Striker (パトストライカー, Pato Sutoraikā): Deka Red's personal six-wheeled, police car-themed Deka Machine that forms the head and torso of Dekaranger Robo. It is also equipped with a pair of Striker Arms (ストライカーアーム, Sutoraikā Āmu), which allows it to wield the Judgement Sword (ジャッジメントソード, Jajjimento Sōdo) in its Driving Sword (ドライビングソード, Doraibingu Sōdo) formation. Pat Gyrer (パトジャイラー, Pato Jairā): Deka Blue's personal autogyro-themed Deka Machine that forms the left leg of Dekaranger Robo. It is also equipped with the Gyro Vulcan (ジャイロバルカン, Jairo Barukan) Gatling guns, the Gyro Wapper (ジャイロワッパー, Jairo Wappā) handcuffs, and the Magnet Wire (マグネワイヤー, Magune Waiyā). PaTrailer (パトレーラー, Patorērā): Deka Green's personal armored semi-trailer truck-themed Deka Machine that forms the right leg of Dekaranger Robo. It also carries the Judgement Sword and the Signal Cannon (シグナルキャノン, Shigunaru Kyanon) into battle. Pat Armor (パトアーマー, Pato Āmā): Deka Yellow's personal armored car-themed Deka Machine that forms the right arm of Dekaranger Robo. It is also equipped with floodlights, which allow it to perform the Armor Attack (アーマーアタック, Āmā Atakku) and Light Flash (ライトフラッシュ, Raito Furasshu) attacks. Pat Signer (パトシグナー, Pato Shigunā): Deka Pink's personal buggy-themed Deka Machine that forms the left arm of Dekaranger Robo. It is also equipped with a large retractable signboard.
== Medical uses == Liraglutide is an anti-diabetic medication used for the treatment of type 2 diabetes or obesity. Liraglutide (Victoza) is indicated as an adjunct to diet and exercise to improve glycemic control in people aged ten years of age and older with type 2 diabetes; and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Liraglutide (Saxenda) is indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in people aged twelve years of age and older with body weight greater than 60 kilograms (130 lb) and obesity; and in adults with overweight in the presence of at least one weight-related comorbid condition.
Pd complexes of BrettPhos catalyze the amination of aryl mesylates and aryl halides. Pd-BrettPhos complexes catalyze the coupling of weak nucleophiles with aryl halides. Such catalysts are selective for the monoarylation of primary amines. Other applications of BrettPhos in catalysis include trifluoromethylation of aryl chlorides, the formation of aryl trifluoromethyl sulfides, and Suzuki-Miyaura cross-couplings. Pd- t-BuBrettPhos complexes catalyze the conversion of aryl triflates and aryl bromides to aryl fluorides as well as the synthesis of aromatic nitro compounds. The bulky AdBrettPhos can be used in the amidation of five-membered heterocyclic halides that contain multiple heteroatoms (such as haloimidazoles and halopyrazoles).
Sources: en.wikipedia.org
=== Neurological === Higher concentrations of TGF-β are found in the blood and cerebrospinal fluid of patients with Alzheimer's disease as compared to control subjects, suggesting a possible role in the neurodegenerative cascade leading to Alzheimer's disease symptoms and pathology. The role of TGF-β in neuronal dysfunction remains an active area of research.
Orthologous sequences provide useful information in taxonomic classification and phylogenetic studies of organisms. The pattern of genetic divergence can be used to trace the relatedness of organisms. Two organisms that are very closely related are likely to display very similar DNA sequences between two orthologs. Conversely, an organism that is further removed evolutionarily from another organism is likely to display a greater divergence in the sequence of the orthologs being studied.
The following is a list of fentanyl analogues (sometimes referred to as fentalogs), and includes both compounds developed by pharmaceutical companies for legitimate medical use, and those which have been sold as designer drugs. The latter have been reported to national drug control agencies such as the DEA, and some to transnational agencies such as the EMCDDA and UNODC. This is not a comprehensive or exhaustive list of fentanyl analogues, as more than 1400 compounds from this family have been described in the scientific and patent literature. However, this list does include many notable compounds that have reached late-stage human clinical trials, and compounds which have been sold as designer drugs, as well as representative examples of significant structural variations reported in the scientific and patent literature. The structural variations among fentanyl analogues can impart profound pharmacological differences between each other, especially regarding potency and efficacy. In the United States, the Drug Enforcement Administration (DEA) placed the class of "Fentanyl-Related Substances" on the list of Schedule I drugs in 2018, making it illegal to manufacture, distribute, or possess fentanyl analogs, with very broad terminology being used in its scheduling. Regarding the temporary control of fentanyl-related substances, Schedule I was extended through December 31, 2024 by Public Law 117-328.
genetic regulatory network (GRN) A graph that represents the regulatory complexity of gene expression. The vertices (nodes) are represented by various regulatory elements and gene products while the edges (links) are represented by their interactions. These network structures also represent functional relationships by approximating the rate at which genes are transcribed.
== Protein classification == Proteins may be classified according to both structural and sequential similarity. For structural classification, the sizes and spatial arrangements of secondary structures described in the above paragraph are compared in known three-dimensional structures. Classification based on sequence similarity was historically the first to be used. Initially, similarity based on alignments of whole sequences was performed. Later, proteins were classified on the basis of the occurrence of conserved amino acid patterns. Databases that classify proteins by one or more of these schemes are available. In considering protein classification schemes, it is important to keep several observations in mind. First, two entirely different protein sequences from different evolutionary origins may fold into a similar structure. Conversely, the sequence of an ancient gene for a given structure may have diverged considerably in different species while at the same time maintaining the same basic structural features. Recognizing any remaining sequence similarity in such cases may be a very difficult task. Second, two proteins that share a significant degree of sequence similarity either with each other or with a third sequence also share an evolutionary origin and should share some structural features also. However, gene duplication and genetic rearrangements during evolution may give rise to new gene copies, which can then evolve into proteins with new function and structure.
Sources: en.wikipedia.org
=== Startup of Poiseuille flow in a pipe === When a constant pressure gradient G = −dp/dx is applied between two ends of a long pipe, the flow will not immediately obtain Poiseuille profile, rather it develops through time and reaches the Poiseuille profile at steady state. The Navier–Stokes equations reduce to
Boomf raised $1m of funding in 2021, but by December 2021 the company had fallen into administration owing £800,000 to creditors, including £146,306 to HM Revenue and Customs. Creditors voluntary liquidation commenced on 4 November 2022.
== Prevalence == Since there is no regular autoantibody screening, patients with LADA are at risk of being diagnosed with type 2 diabetes, which makes it difficult to estimate the prevalence of LADA. Globally, it is estimated that about 8.5% of adults have some form of diabetes and it is estimated that LADA accounts for about 3-12% of all adult diabetes cases. 2015 estimates suggest that up to 10–20% of people with diabetes have LADA.
Actin filaments are often rapidly assembled and disassembled, allowing them to generate force and support cell movement. Assembly classically occurs in three steps. First, the "nucleation phase", in which two to three G-actin molecules slowly join to form a small oligomer that will nucleate further growth. Second, the "elongation phase", when the actin filament rapidly grows by the addition of many actin molecules to both ends. As the filament grows, actin molecules are added to the (+) end of the filament around 10 times faster than to the (−) end, and so filaments tend to primarily grow at the (+) end. Third, the "steady-state phase", where an equilibrium is reached as actin molecules join and leave the filament at the same rate, maintaining the filament's length. While the filament's length remains constant in the steady-state phase, new molecules are constantly being added to the (+) end and falling off the (−) end, a phenomenon called "treadmilling" as a given actin molecule would appear to move along the strand. In isolation, whether a filament will grow or shrink, and how quickly, are determined by the concentration of G-actin around the filament; however, in cells, the dynamics of actin filaments are heavily influenced by various actin-binding proteins.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
Standard practice is a desiccated container at −20 °C, protected from light and kept sealed between uses. Letting the vial reach room temperature before opening reduces condensation on the powder. Repeated warming and cooling of the whole container is generally avoided.